| J2350 | Injection, ocrelizumab, 1 mg | 1 | 10 | 330 | $11,290 | $4M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4 | 100 | 2,830 | $80 | $3.8M |
| J9271 | Injection, pembrolizumab, 1 mg | 9 | 10 | 270 | $3,820 | $2.9M |
| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 15 | 110 | 5,950 | $270 | $2.6M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2 | 10 | 1,290 | $1,830 | $2.4M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 48 | 230 | 5,440 | $90 | $1.8M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 45 | 230 | 6,220 | $100 | $1.8M |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 28 | 190 | 5,130 | $100 | $1.8M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 20 | 30 | 660 | $100 | $1.5M |
| J2323 | Injection, natalizumab, 1 mg | 2 | 10 | 1,110 | $1,460 | $1.5M |